DRHP Status : Not Filed
1400
P&L Statement | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenue | 2431 | 2795 | 3037 | 3069 |
Cost of Material Consumed | 1149 | 1901 | 1923 | 1697 |
Gross Margins | 52.74 | 31.99 | 36.68 | 44.71 |
Change in Inventory | 120 | -262 | 18 | 137 |
Employee Benefit Expenses | 211 | 219 | 202 | 219 |
Other Expenses | 494 | 580 | 514 | 574 |
EBITDA | 457 | 357 | 380 | 442 |
OPM | 18.8 | 12.77 | 12.51 | 14.4 |
Other Income | -120 | 87 | 93 | 108 |
Finance Cost | 65 | 45 | 46 | 39 |
D&A | 112 | 90 | 87 | 89 |
EBIT | 345 | 267 | 293 | 353 |
EBIT Margins | 14.19 | 9.55 | 9.65 | 11.5 |
PBT | 160 | 308 | 339 | 422 |
PBT Margins | 6.58 | 11.02 | 11.16 | 13.75 |
Tax | 93 | 89 | 97 | 90 |
PAT | 67 | 219 | 242 | 332 |
NPM | 2.76 | 7.84 | 7.97 | 10.82 |
EPS | 31.46 | 102.82 | 113.62 | 155.87 |
Financial Ratios |
2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Operating Profit Margin | 18.8 | 12.77 | 12.51 | 14.4 |
Net Profit Margin | 2.76 | 7.84 | 7.97 | 10.82 |
Earning Per Share (Diluted) | 31.46 | 102.82 | 113.62 | 155.87 |
Assets | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Fixed Assets | 640 | 602 | 698 | 687 |
CWIP | 83 | 119 | 150 | 138 |
Investments | 711 | 899 | 1464 | 2333 |
Trade Receivables | 721 | 785 | 758 | 903 |
Inventory | 356 | 641 | 689 | 525 |
Other Assets | 753 | 798 | 373.5 | 571 |
Total Assets | 3264 | 3844 | 4132.5 | 5157 |
Liabilities | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Share Capital | 21.3 | 21.3 | 21.3 | 21.3 |
FV | 10 | 10 | 10 | 10 |
Reserves | 1931 | 2199 | 2896 | 3973 |
Borrowings | 654 | 679 | 559 | 363 |
Trade Payables | 373 | 818 | 439 | 477 |
Other Liabilities | 284.7 | 126.7 | 217.2 | 322.7 |
Total Liabilities | 3264 | 3844 | 4132.5 | 5157 |
Name | Holding |
---|---|
K.K.Modi Investment And Financial Services | 43.87% |
U.P. State Industrial Development Corporation | 9.45% |
Rajputana Developers Limited | 8.89% |
APMS Investment Fund Limited (FII) | 6.81% |
Modi Industries Limited | 5.08% |
Others | 25.9% |
Coming soon...
Indofil Industries Limited excels in both Agricultural Chemicals (ABD) and Indofil Innovative Solutions (IIS). The company boasts robust manufacturing, a results-oriented R&D team, and strong domestic and international distribution.
Indofil exports Mancozeb formulations to over 120 countries. In India, they are known for strategically marketing a wide range of agricultural products, including insecticides (including IGRs), fungicides (Mancozeb, Tricyclazole, Zineb), bactericides, herbicides, acaricides, surfactants, and Plant Growth Regulators (PGRs), all driven by a "Crop Care Concept."
Indofil Innovative Solutions provides cutting-edge products for various industries, including Leather, Textile, Paints, Plastics, and Construction Chemicals.
With a long track record of success, Indofil prioritises customer proximity, 24/7 accessibility, and trust. They believe partnerships are key to growth, aiming to maximise business potential, deliver value, and create new markets to meet current and future strategic goals.
Click here to visit the official website of Indofil Industries.
Strengths:
Robust Financial Performance: In the fiscal year 2024, Indofil reported revenues of ₹3,118 crore, achieving a 45% year-over-year growth in Profit After Tax (PAT).
Strategic Investments: The company holds substantial investments, including 6,545,020 shares in Godfrey Philips India Ltd., valued at approximately ₹5,389.8 crore as of May 2024. This holding enhances Indofil's intrinsic value per share.
Industry Growth Potential: The global agrochemical market is projected to grow at a compound annual growth rate (CAGR) of 3.9% between 2024 and 2030, positioning Indofil to benefit from increased demand.
Global Presence: With operations in over 90 countries, Indofil's extensive distribution network positions it to capture a significant share of the expanding global agrochemical market.
Weaknesses:
Liquidity Concerns: Unlisted shares inherently have lower liquidity compared to listed counterparts, potentially making it challenging for investors to buy or sell shares promptly.
Valuation Discrepancies: Indofil's unlisted shares are trading at a discount compared to their intrinsic value, partly due to internal family disputes affecting investor confidence.
Absence of IPO Plans: The lack of immediate plans for an Initial Public Offering (IPO) limits potential exit strategies for investors, contributing to the current undervaluation of shares.
Price Volatility: The unlisted nature of the shares can lead to higher price volatility due to limited trading activity and market speculation.